St. James's Institute of Oncology, St. James's University Hospital, Leeds Teaching Hospitals, Leeds, West Yorkshire, UK.
Radiat Oncol. 2010 Dec 21;5:121. doi: 10.1186/1748-717X-5-121.
Chemo-radiotherapy offers an alternative to primary surgery and adjuvant therapy for the management of locally advanced stage IV squamous cell carcinomas of the tonsil.
A retrospective analysis was performed of the outcomes of 41 patients with locoregionally advanced squamous cell carcinoma of the tonsil treated non-surgically at the Yorkshire Cancer Centre between January 2004 and December 2005. Due to long radiotherapy waiting times, patients received induction chemotherapy with cisplatin and 5-fluorouracil followed by either cisplatin concurrent chemoradiotherapy or radiotherapy alone.
Median age was 55 years (range 34-76 years) and 28 (68%) patients were male. 35/41 patients (85%) received 2 or more cycles of induction chemotherapy. Following induction chemotherapy, 32/41 patients (78%) had a clinical response. Concomitant chemotherapy was given to 30/41 (73%). All patients received the planned radiotherapy dose with no delays. There were no treatment related deaths. Six (15%) patients had gastrostomy tubes placed before treatment, and 22 (54%) required nasogastric tube placement during or after treatment for nutritional support. 17 patients required unplanned admissions during treatment for supportive care. At 4 months post treatment assessment 35 out of 41 (85%) patients achieved complete clinical and radiographic response. Median follow-up is 38 months (8-61 months). Local and regional control rate in complete responders at 3 years was 91%. Distant metastases have been found in 4 (9.8%) patients. Three year progression-free survival rate in all patients is 75%. The 3-year cause specific survival and overall survival are 75% and 66% respectively.
Cisplatin-based induction and concurrent chemoradiotherapy provides excellent tumour control with acceptable toxicity for patients with locally advanced tonsillar cancer.
放化疗为局部晚期 IV 期扁桃体鳞状细胞癌的治疗提供了替代手术和辅助治疗的选择。
对 2004 年 1 月至 2005 年 12 月在约克郡癌症中心接受非手术治疗的 41 例局部晚期扁桃体鳞状细胞癌患者的结果进行回顾性分析。由于放疗等待时间较长,患者接受顺铂和 5-氟尿嘧啶诱导化疗,然后接受顺铂同期放化疗或单纯放疗。
中位年龄为 55 岁(范围 34-76 岁),28 例(68%)为男性。41 例患者中有 35 例(85%)接受了 2 个或更多周期的诱导化疗。诱导化疗后,32 例(78%)患者有临床反应。30 例(73%)患者接受了同期化疗。所有患者均按计划接受放疗,无延迟。无治疗相关死亡。6 例(15%)患者在治疗前放置了胃造口管,22 例(54%)患者在治疗期间或之后需要放置鼻胃管以进行营养支持。17 例患者在治疗期间需要计划外住院以进行支持治疗。治疗后 4 个月评估时,41 例中有 35 例(85%)患者完全达到临床和影像学反应。中位随访时间为 38 个月(8-61 个月)。完全缓解者 3 年局部和区域控制率为 91%。4 例(9.8%)患者发现远处转移。所有患者的 3 年无进展生存率为 75%。3 年的无病生存率和总生存率分别为 75%和 66%。
顺铂为基础的诱导和同期放化疗为局部晚期扁桃体癌患者提供了极好的肿瘤控制,毒性可接受。